摘要
我们报告了在组成型肝特异性启动子存在条件下,利用编码人胰岛素原基因的单次假腺相关病毒8型(ssAAV2/8)载体给药进行全身给药,对STZ诱导糖尿病小鼠高血糖进行校正。通过体内剂量滴定实验,我们确定最佳剂量范围,实现了保持正常的血糖含量,或保持小鼠至少9个月处于糖尿病状态,对某些动物能使其持续保持糖尿病状态超过1年,并伴随人类C-肽分泌和体重增加。胰岛素基因的DNA密码子进一步优化,导致在密码子优化治疗的动物血液中分泌约3-10倍的C肽,从而降低载体粒子数量,而使血糖水平降低至相同程度。胰岛素构成性分泌与载体的单次给药,对某些糖尿病患者具有治疗价值。
关键词: 基因治疗,糖尿病,胰岛素,AAV,密码子优化。
Current Gene Therapy
Title:Correction of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene
Volume: 16 Issue: 1
Author(s): Gan Shu Uin, Notaridou Maria, Fu Zhen Ying, Lee Kok Onn, Sia Kian Chuan and Nathwani Amit Chunilal, Della Peruta Marco and Calne Roy Yorke
Affiliation:
关键词: 基因治疗,糖尿病,胰岛素,AAV,密码子优化。
摘要: We report the correction of hyperglycemia of STZ induced diabetic mice using one intravenous systemic administration of a single stranded serotype 8 pseudotyped adeno-associated virus (ssAAV2/8) vector encoding the human proinsulin gene under a constitutive liver specific promoter. In vivo dose titration experiments were carried out and we identified an optimal range that achieved maintenance of euglycaemia or a mild diabetic condition for at least 9 months and ongoing to beyond 1 year for some animals, accompanied by human C-peptide secretion and weight gain. Further DNA codon optimization of the insulin gene construct resulted in approximately 3-10 times more human C-peptide secreted in the blood of codon optimized treated animals thereby reducing the number of vector particles required to achieve the same extent of reduction in blood glucose levels as the non-codon optimized vector. The constitutive secretion of insulin achieved with a single administration of the vector could be of therapeutic value for some diabetic patients.
Export Options
About this article
Cite this article as:
Gan Shu Uin, Notaridou Maria, Fu Zhen Ying, Lee Kok Onn, Sia Kian Chuan and Nathwani Amit Chunilal, Della Peruta Marco and Calne Roy Yorke , Correction of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene, Current Gene Therapy 2016; 16 (1) . https://dx.doi.org/10.2174/1566523216666160122113958
DOI https://dx.doi.org/10.2174/1566523216666160122113958 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Asafoetida, Natural Medicine for Future
Current Nutrition & Food Science Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Roles and Therapeutic Potential of Metallothioneins in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets Pharmacokinetics Prediction and Drugability Assessment of Diphenylheptanoids from Turmeric (Curcuma longa L)
Medicinal Chemistry Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design